Archived: 5th Winter Conference
on Medicinal & Bioorganic Chemistry
January 26th - 31st 2003
Steamboat Springs Resort, Colorado
Agenda
Sunday, January 26th 2003
Round Table Discussion on the Foreseeable Future of Medicinal & Bioorganic Chemistry
Program Chair: Gary L. Grunewald, University of Kansas
Monday, January 27th 2003
C-H Activation: The New Generation
Program Chair: Victor Snieckus, Queen’s University
Metal Catalyzed Reactions of Pharmaceutical Value
C-H Activation: The Last Generation Tries to Keep Up with the Next Generation
Catalytic Regioselective Functionalization of Alkanes and Arenes with Borane Reagents
C-H Activation. An Overview
Chemical Genomics in Drug Discovery
Program Chair: Daniel Flynn, Deciphera Pharmaceuticals
Approaches and Opportunities in Chemical Genomics
Chemical Genetics
Organizing Research by Gene Family
Fragment-Based Diversity on Chemical Microarrays: Discovery from a Different Angle
Tuesday, January 28th 2003
New Developments in High-Throughput Screening Methodologies
Program Chair: Michael Rafferty, Pfizer Global Research & Development
High Throughput Pharmacology in Drug Discovery
Cell-Based Assay Development Using GeneDriver
ALIS: Ultra High Capacity Affinity Screening for Drug Discovery
Increased exploitation of the chemical space through economic sensitivity screening
Innovations in Process & Scale-Up Chemistry
Program Chair: Tony Barrett, Imperial College /Mike Lipton, Pharmacia Corp.
Optimisation by Design
Innovation in Chemical Syntheses from Bench to Production
Fluorous Methods in Synthesis of Small Molecules
Microfluidic Routes to the Controlled Synthesis of Small Molecules
Germany Ionic Liquids: A New Concept for Synthesis in Pharmaceutical Chemistry and Fine Chemicals Productions
Wednesday, January 29th 2003
General Papers | Session I
Program Chair: Michael VanNieuwenhze, University of California – San Diego
KEYNOTE
Program Chair: Chi-Huey Wong, Scripps Research Institute
Thursday, January 30
General Papers | Session II
Program Chair: Dennis Dean, Merck Research Institute
Chemokine Receptor Antagonists – HIV Targets
Program Chair: Wieslaw M. Kazmierski, GlaxoSmithKline
The Salk Institute for Biological Studies Fusion Inhibitors: Closing the Door on HIV
The Development of Potent, Orally Active Antagonists of the Human CCR5 Receptor as Anti-HIV Agents
The Discovery of CCR5 Antagonists from GPCR Targeted Combinatorial Library
The Discovery of Potent, Orally Bioavailable CCR5 Antagonists for the Potential Treatment of HIV Infection
Friday, January 31st 2003
Chemokine Receptor Antagonists – Inflammation Targets
Program Chair: Lihu Yang, Merck and Co.
Chemokine Receptor Antagonism as Potential Therapeutic Targets in Inflammatory Diseases
Discovery of Selective, Potent, Orally Available CCR1 Receptor Antagonists
Optimization of Small Molecule CCR2b Antagonists
Pyrrolidine Antagonists of the CCR3 Chemokine Receptors
Evolution in Our Design of Selective Inhibitors of Human Nitric Oxide Synthases from Cyclic Amidines to Hybrid Iminohomopiperidinium Amino Acid
Media Sponsors
